Target intelligence / Profile preview

Fanconi anemia group G protein (FANCG)

Target
FANCG
Molecular classification
DNA repair protein, Component of multiprotein complex, Other (FA core complex subunit)
01

Overview

Fanconi anemia group G protein (FANCG) is a core component of the Fanconi anemia (FA) repair pathway, responsible for repairing DNA interstrand cross-links (ICLs) that block DNA replication. FANCG is one of several proteins that together form the FA core complex, which facilitates the monoubiquitination of FANCD2 and FANCI, activating downstream DNA repair. FANCG is essential for maintaining genomic integrity by preventing chromosomal breakage during replication stress. Deficiency or mutation in FANCG causes Fanconi anemia complementation group G, leading to a phenotype of bone marrow failure, developmental abnormalities, and increased cancer risk, especially for acute myeloid leukemia and various solid tumors. FANCG-deficient cells are hypersensitive to DNA cross-linking agents (e.g., cisplatin, mitomycin C). There are no direct therapies targeting FANCG, but its genetic status is valuable for diagnosis, prognosis, and guiding the use of DNA-damaging chemotherapeutics.

Other names
Fanconi anemia group G proteinFANCGXRCC9Protein FACGFAGDNA repair protein XRCC9X-ray repair complementing defective repair in Chinese hamster cells 9
02

Mechanism of action

Not applicable, as there are no direct drugs targeting FANCG; indirect effects relate to hypersensitivity to cross-linking chemotherapies.

03

Biological functions

DNA repairMaintenance of genomic stabilityCellular response to DNA cross-linking agentsHomologous recombination
04

Disease associations

Cancer (notably predisposition, e.g., leukemia and solid tumors)Bone marrow failure syndromesDevelopmental disorders (as part of Fanconi anemia phenotype)
05

Safety considerations

Loss or mutation leads to Fanconi anemia, with increased cancer predisposition, bone marrow failure, and cellular hypersensitivity to DNA damaging agents
06

Interacting drugs

None are clinically approved that directly target FANCG; however, FANCG-deficient cells show hypersensitivity to DNA cross-linking agents such as cisplatin and mitomycin C
07

Biomarkers

FANCG mutation or deficiency (biomarker for Fanconi anemia diagnosis and risk stratification)

Beyond the preview

Go deeper on Fanconi anemia group G protein (FANCG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fanconi anemia group G protein (FANCG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call